The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David A Hess, PhD
Robarts Research Institute, London, Ontario
Principal Investigator - Subodh Verma, MD, PhD
Unity Health Toronto
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Oshawa Clinic
Oshawa, Ontario, Canada
- Diagnostic Assessment Centre
Scarborough Village, Ontario, Canada
- Langstaff Medical Clinic
Vaughan, Ontario, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Sept 2020
- Primary completion
- 25 May 2023
- Completion
- 25 May 2023
- Last update posted
- 2 Apr 2024
- Registered enrollment
- 70
- Registry id
- NCT04562467
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.